The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Have histologically confirmed adenocarcinoma of the prostate
Have disease that is metastatic at the time of the screening as determined by the investigator
Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per milliliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
Have progressed on at least 1 novel androgen receptor pathway inhibition (ARPI) but received no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
Known history of either brain or leptomeningeal prostate cancer metastases
Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
Prior or concurrent second malignancy (other than the disease under study) because the natural history or treatment could interfere with study endpoints
Received cytotoxic chemotherapy for prostate cancer in any setting
Parallel
Pasritamig
DrugPasritamig will be administered.
Docetaxel
DrugDocetaxel will be administered.
Prednisone
DrugPrednisone will be administered.
Radiographic Progression-Free Survival (rPFS) Assessed by BICR
rPFS is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first.
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause.
Time to Symptomatic Progression (TSP)
TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation for skeletal or pelvic symptoms, the need for tumor-related orthopedic surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms.
Time to Subsequent Therapy (TST)
TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy.
Time to Skeletal-Related Event (TSRE)
TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following: the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression.
Click on the lead sponsor to view all of their trials.
